Elevation Oncology

Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in Boston, MA.

Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology is also exploring anti-HER3 ADCs and is close to nominating a candidate for clinical development in this area.

Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)

-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program.  The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

Corbus Pharmaceuticals Holdings

Personalized health screening from a “smart toilet”

All Three of Our Analysts Agree

--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 – -- Raised approximately $17.0M in net proceeds through at-the-market (ATM) facility and refinanced debt facility with K2 Health Ventures; cash runway into the fourth quarter of 2025 -- BOSTON , March 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements. "We are entering 2024 with tremendous momentum across our pipeline of differentiated ADC therapies," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements

Digital World Acquisition Corp

Super Micro Computer

Recently, I watched portions of a YouTube video that tangentially but importantly related to overbought stocks to sell. An options trader boasted about an 80% success rate with his system, which sounded like nonsense.

Trim the Fat: 3 Overbought Stocks Poised for a Pullback

-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are excited to share preclinical proof-of-concept data for our HER3-ADC program.

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D.

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.

PHILADELPHIA , Feb. 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's investors. The investigation seeks to determine whether Elevation Oncology and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 10:30 AM ET in Boston, MA.

Elevation Oncology to Participate in Upcoming Investor Conferences

Beamr Imaging Ltd

MicroCloud Hologram Inc

The stock market has seen a remarkable surge in recent months, climbing 21% since the end of October. Rallies as strong as this one tend to yield several stock winners, which in this case are primarily GenAI-focused companies.

3 Stock Winners That Are Up 400% or More in 2024

-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has expanded its ongoing Phase 1 clinical trial of EO-3021 outside the United States, dosing the first patient in Japan. This trial is evaluating the safety, tolerability and preliminary anti-tumor activity of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic or esophageal cancers.

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors.

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy --  -- Announcing HER3-targeting ADC as Second Pipeline Program; Development Candidate Nomination in 2024-- -- Entering 2024 in Strong Financial Position, with Cash into 2H 2025 -- BOSTON , Jan. 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming 2024 milestones. "Our vision is to leverage our ADC and oncology drug development expertise to deliver innovative, selective cancer therapies to millions of patients with significant unmet needs.

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones

BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 8:30 am ET.

Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference

-- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expected in 1H 2025 -- BOSTON , Nov. 2, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent business achievements. "In the third quarter, we achieved a key milestone in our efforts to establish EO-3021 as a potential best-in-class anti-Claudin 18.2 ADC therapy, initiating patient enrollment in our Phase 1 clinical trial," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.

Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Chief Executive Officer of Elevation Oncology, will present at the H.C.

Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. "The dosing of the first patient is a major milestone in evaluating EO-3021's potential benefit for these patients," said Valerie Malyvanh Jansen, M.D.

Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Closed underwritten public offering generating net proceeds of $46.5 million, providing cash runway into the second half of 2025 On track to initiate Phase 1 clinical trial of EO-3021 in the US in the second half of 2023 NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent business achievements. "The compelling initial clinical data presented at ASCO 2023 by our partner CSPC Pharmaceutical Group Limited (CSPC) are further evidence for why we believe EO-3021 to be a differentiated and potentially best-in-class antibody-drug conjugate targeting cancer cells expressing Claudin 18.2," said Joseph Ferra, Chief Executive Officer of Elevation Oncology.

Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

NEW YORK , July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer.

Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

Elevation Oncology (NASDAQ: ELEV ) stock is taking a beating on Friday after the healthcare company announced a public stock offering. That public offering of ELEV stock has the company selling 17,810,000 shares at a price of $2.25 each.

Why Is Elevation Oncology (ELEV) Stock Down 26% Today?

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an underwritten public offering of (i) 17,810,000  shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000 shares of common stock and (ii) accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant is $2.2500.

Elevation Oncology Announces Pricing of $50 Million Public Offering

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced  a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase shares of common stock and (ii) of accompanying warrants to purchase shares of common stock. All of the shares of common stock, pre-funded warrants and accompanying warrants are being offered by Elevation Oncology.

Elevation Oncology Announces Launch of Proposed Public Offering

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to initiate Phase 1 clinical trial in the US in the second half of 2023 NEW YORK , June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023, in Chicago, IL.

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

Elevation Oncology NASDAQ: ELEV is a biotech company that focuses on discovering and developing cancer therapies. The company aims to treat patients with various solid tumors with significant unmet medical needs.

Steve Cohen's Point72 Disclosed 8.7% Stake In Elevation Oncology

Elevation Oncology (NASDAQ: ELEV ) stock is on the rise Friday despite a lack of news from the pharmaceutical company. There's no news that explains why shares of ELEV stock are taking off today.

News for Elevation Oncology Stock (ELEV)